Halozyme, Inc.’s Post

View organization page for Halozyme, Inc., graphic

18,864 followers

Based on the new European patent for ENHANZE®, Halozyme recently raised our full year 2024 financial guidance and updated our 5-year financial outlook. "We are pleased to be able to raise our full year 2024 financial guidance and 5-year financial outlook, which now reflect the original royalty rate for DARZALEX SC in Europe from the granting of this new European patent, which is valid through March 6, 2029," said Dr. Helen Torley, president and chief executive officer of Halozyme. For the full year 2024, the Company expects: • Total revenue of $935 million to $1,015 million, representing growth of 13% to 22% over 2023, primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED®. • Revenue from royalties of $520 million to $555 million, representing growth of 16% to 24% over 2023. • Adjusted EBITDA of $555 million to $615 million, representing growth of 30% to 44% over 2023. • Non-GAAP diluted earnings per share of $3.65 to $4.05, representing growth of 32% to 46% over 2023. The Company's earnings per share guidance does not consider the impact of potential future share repurchases. The full press release can be found here: https://ow.ly/7y1U50SbflM Halozyme also provided additional details on the new European patent and our 5-year financial outlook on a conference call; a recording is available here: https://ow.ly/5Yjp50SbflL

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics